| Name | Title | Contact Details |
|---|
We are a committed team of engineers and market-makers who believe in the power of technology to deliver lasting change in tackling the colossal problem of microplastic pollution in our natural environment. The health of the worlds oceans and life on Earth depends on our contribution and the actions we take now as an organisation - there is no time to waste.
KACE Company, based in Ashburn, VA, is a federal government contractor with over 30 years of experience in linguistics and related services. The company specializes in mission-critical services that enhance national security, public safety, and government operations. As one of the largest language services providers to the U.S. federal government, KACE employs over 1,500 people and is recognized as a Hispanic American Owned and Minority Owned business. KACE offers a range of professional services tailored to government needs, including program optimization, intelligence and analytics, and specialized language services. Their program optimization focuses on data-driven strategies to improve performance and efficiency. In intelligence and analytics, KACE extracts insights from large datasets to support various missions. Their language services encompass transcription, translation, interpretation, and language analysis, ensuring accurate communication across more than 150 languages and dialects.
Meyer Laboratory, also known as Meyer Lab, is a U.S.-based chemical manufacturer that specializes in industrial and institutional cleaning chemicals and application systems. Founded in 1978 by Russ Meyer, the company has established itself as a leader in the North American market for industrial cleaning solutions. Meyer Lab focuses on delivering customized cleaning programs that meet the specific needs of its customers. The company offers a wide range of services, including tailored cleaning programs that aim to reduce chemical and labor costs, maintenance services for cleaning equipment, and training for effective product use. Meyer Lab also provides inventory management assistance and supplies advanced dispensing systems to enhance safety and efficiency in chemical use. Their product portfolio features various hard surface cleaning chemicals, such as degreasers, disinfectants, sanitizers, and surfactant blends, which are designed for multiple industrial and manufacturing markets. Meyer Lab is committed to supporting environmental initiatives by providing effective and efficient cleaning solutions.
Global Synergizers is a social impact consulting firm that collaborates with corporates, social product innovators and social organisations to enable collective impact. Our programs are aligned with UN SDGs and address issues at the local level to create a systemic effect. If you would like to collaborate with us, write to us on info@globalsynergizers.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.